Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Melissa officinalis (lemon balm) contains rosmarinic acid and citral that modulate GABA neurotransmission and reduce cortisol levels. Clinical studies demonstrate significant improvements in anxiety symptoms and sleep quality within 15 days of supplementation.
Origin & History
Melissa officinalis (lemon balm) is a perennial herb in the Lamiaceae family native to southern Europe, the Mediterranean region, and Central Asia. The leaves are typically extracted using aqueous or hydroalcoholic methods to produce standardized extracts like Cyracos® or phospholipid-based formulations like Relissa™.
Research Narrative (Provisional)
Clinical evidence includes a pilot trial (n=20) showing 95% anxiety response and 100% insomnia response with Cyracos® extract (PMID: 22043994), and a larger RCT (n=100) demonstrating significant improvements in depression, anxiety, stress, and sleep quality with 400mg/day phospholipid-based extract (PMID: 37927585). Meta-analyses confirm positive effects on depression and anxiety (PMID: 41754356), with additional RCTs showing benefits in diabetic patients (PMID: 37131158).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Melissa officinalis (lemon balm) is a low-calorie herb with primary value derived from its bioactive phytochemicals rather than macronutrient content. Macronutrient composition per 100g dry weight: protein ~14-20g, carbohydrates ~50-60g (including dietary fiber ~20-25g), fat ~5-7g. Key micronutrients include vitamin C (~150mg/100g fresh weight), vitamin A (beta-carotene precursors, ~3000-4000 IU/100g), calcium (~694mg/100g dry weight), magnesium (~65-75mg/100g dry weight), potassium (~450-500mg/100g dry weight), iron (~14-16mg/100g dry weight), and zinc (~1.5-2mg/100g dry weight). Bioactive compounds are the primary functional constituents: rosmarinic acid (0.5-3% dry weight, often 1-2% in standardized extracts) — the principal polyphenol with antioxidant and anxiolytic properties, with moderate oral bioavailability (~40% absorbed in small intestine); hydroxycinnamic acid derivatives including caffeic acid, chlorogenic acid, and luteolin-7-glucoside (collectively 1-4% dry weight); flavonoids including luteolin, apigenin, quercetin, and kaempferol (0.1-0.5% total flavonoids); triterpenic acids including ursolic acid and oleanolic acid (~0.5-1% dry weight); essential oil constituents (0.01-0.3% by weight) comprising citral (geranial + neral, 30-40% of volatile fraction), citronellal (~5-10%), linalool (~5%), beta-caryophyllene (~10-15%), and geraniol (~5%); monoterpene glycosides including melittoside; and salvianolic acids. GABA-transaminase inhibitory activity is attributed to rosmarinic acid and related phenolics, contributing to anxiolytic effects. Bioavailability note: rosmarinic acid bioavailability is enhanced when consumed with lipids; essential oil compounds are highly bioavailable via inhalation and oral routes; standardized extracts (e.g., Cyracos, 500mg containing ≥7% rosmarinic acid and ≥15% hydroxycinnamic acid derivatives) are used in clinical research and show superior pharmacokinetic profiles compared to crude herb preparations.
Reported Mechanism (Provisional)
Melissa officinalis exerts its effects primarily through rosmarinic acid and citral, which enhance GABAergic neurotransmission by inhibiting GABA transaminase and modulating GABA-A receptors. The herb also reduces cortisol levels through hypothalamic-pituitary-adrenal axis modulation and exhibits acetylcholinesterase inhibition, contributing to cognitive and anxiolytic effects.
Clinical Narrative (Provisional)
A 15-day pilot trial demonstrated a 95% response rate for anxiety reduction, with 70% of participants showing very significant improvement using 300mg twice daily. Sleep quality studies show 100% responder rates with significant PSQI score improvements in controlled trials. While preliminary evidence is promising, most studies involve small sample sizes and short durations, requiring larger randomized controlled trials for definitive efficacy confirmation.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.